Valuation: MaaT Pharma

Market Cap 57.28M 66.88M 53.59M 49M 92.54M 6.38B 93.37M 632M 246M 3.22B 251M 246M 10.65B P/E 2026 *
-1.59x
P/E 2027 * -2.73x
Enterprise Value 68.59M 80.08M 64.17M 58.67M 111M 7.64B 112M 757M 295M 3.85B 301M 294M 12.75B EV / Sales 2026 *
7.03x
EV / Sales 2027 * 3.18x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -
1 day-0.16%
1 week+2.18%
Current month+9.35%
1 month+11.56%
3 months-6.61%
6 months-58.36%
Current year-36.80%
1 week 2.9
Extreme 2.9
3.4
1 month 2.72
Extreme 2.725
3.4
Current year 2.32
Extreme 2.32
8.62
1 year 2.32
Extreme 2.32
8.62
3 years 2.32
Extreme 2.32
9.96
5 years 2.32
Extreme 2.32
14.4
10 years 2.32
Extreme 2.32
14.4
Manager TitleAgeSince
Chief Executive Officer - 2013-12-31
Director of Finance/CFO 59 2024-10-31
Chief Tech/Sci/R&D Officer - 2024-06-23
Director TitleAgeSince
Director/Board Member - 2013-12-31
Director/Board Member 57 2013-12-31
Chairman - 2015-12-31
Date Insider Type Main position Quantity % Market Cap.
1/29/26
Seventure Partners SA
SellCompany 25,423 0.1356%
1/28/26
Seventure Partners SA
SellCompany 57,964 0.3091%
1/14/26
Seventure Partners SA
SellCompany 4,755 0.0254%
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%+2.18%-46.67%-51.59% 66.95M
+3.31%-3.53%+71.28%+104.57% 69.06B
+1.74%+2.81%+55.45%+88.75% 63.06B
+1.09%+24.51%+2.86%-4.20% 28.34B
-0.07%-3.45%-6.06%+464.93% 27.07B
+7.41%+13.08%+58.57%+17.04% 25.45B
+3.98%+4.37%+39.87%-15.08% 19.69B
+1.02%+5.67%+273.94%+420.34% 19.19B
+0.10%+0.19%+12.19%+550.31% 15.95B
+3.98%+8.41%+46.83%+160.78% 13.52B
Average +2.25%+3.78%+50.83%+173.59% 28.14B
Weighted average by Cap. +2.53%+2.95%+59.32%+157.92%

Financials

2026 *2027 *
Net sales 9.75M 11.38M 9.12M 8.34M 15.75M 1.09B 15.89M 108M 41.92M 548M 42.73M 41.8M 1.81B 28.88M 33.71M 27.02M 24.7M 46.65M 3.22B 47.07M 319M 124M 1.62B 127M 124M 5.37B
Net income -31.69M -37M -29.65M -27.11M -51.2M -3.53B -51.66M -350M -136M -1.78B -139M -136M -5.89B -15.31M -17.87M -14.32M -13.1M -24.73M -1.71B -24.95M -169M -65.82M -860M -67.1M -65.63M -2.85B
Net Debt 11.3M 13.2M 10.58M 9.67M 18.26M 1.26B 18.42M 125M 48.6M 635M 49.54M 48.46M 2.1B 34.5M 40.28M 32.27M 29.51M 55.73M 3.84B 56.23M 381M 148M 1.94B 151M 148M 6.41B
Logo MaaT Pharma
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival. A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Employees
56
Date Price Change Volume
26-08-25 €3.040 -0.16% 32,349
26-08-24 €3.045 -4.55% 80,235
26-08-21 €3.190 +2.24% 131,751
26-08-20 €3.120 -0.95% 77,249
26-08-19 €3.150 +7.51% 164,209
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.040EUR
Average target price
6.500EUR
Spread / Average Target
+113.82%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MAAT Stock